Background: Lymphocytic infiltration at diagnosis is prognostic in EOC, however, the impact of NACT on tumour infiltrating lymphocytes (TILs) or PD-L1 expression remains poorly described.
Introduction
There is increasing evidence that the host immune system has a role in the control of cancer growth, and tumour infiltrating lymphocytes (TILs) have been repeatedly associated with improved survival in EOC [1] [2] [3] [4] [5] . Currently, there is no standardized approach to evaluating TILs in EOC, the focus has been on intratumoural subtypes, with high levels of CD8þ TILs most strongly and consistently associated with improved survival [1] [2] [3] 6] . In contrast, in breast cancer, where both sTILs and ieTILs have been assessed as independent parameters, sTILs have emerged as a stronger, more reproducible prognostic marker than ieTILs [7, 8] , and a recommended method of evaluation has been published by the International TILs Working Group [8] .
The majority of patients with EOC present with advanced disease and the cornerstone of management is platinum-based chemotherapy and cytoreductive surgery [9, 10] . Despite initial chemosensitivity, most patients relapse and ultimately platinumresistance ensues resulting in a poor 5-year survival of 45%. In the hope of emulating the success seen in other tumours, attention has turned to immunotherapy as a new strategy to improve survival in EOC [10] . The most encouraging results in other tumour types have come from drugs targeting the PD-L1/ programmed death-1 (PD-1) axis. In EOC, activity in unselected, heavily pre-treated patients has been modest with overall response rates of only 15% [11] , highlighting the urgent need for novel immunotherapy strategies and validated immune biomarkers to guide patient selection. Immunotherapies may be more active in the context of small volume tumour burden and before immune exhaustion.
While the prognostic value of pre-chemotherapy ieTILs has been demonstrated in EOC, and data is available on the expression of PD-L1, little is known about the evolution of these parameters with chemotherapy. Based on the strength of evidence in breast cancer for sTILs as a biomarker, and the recognized prognostic value of the intra-epithelial infiltrate in EOC we chose to evaluate both compartments. Our hypotheses were that the level of TILs and PD-L1 expression would be significantly altered by chemotherapy, and that sTILs would be prognostic both at diagnosis and post-NACT. We sought to characterize the post-NACT tumour sample in an effort to identify patients who may benefit from immunotherapy as maintenance following primary treatment.
Patients and methods

Study population
Tumour samples were retrospectively retrieved from the Gustave Roussy Cancer Center biobank of 150 consented patients with a confirmed histological diagnosis of EOC and available sequential samples pre-, postchemotherapy and/or at relapse. Pre-chemotherapy samples were obtained from biopsy during diagnosis/laparoscopy or primary surgery. Post-chemotherapy samples were obtained during cytoreductive surgery. Relapse samples were obtained at subsequent progression. At interval surgery, samples were selected on the basis of greatest viable tumour cellularity, necrotic samples were excluded. In a few patients with complete pathological response and no viable residual tumour, immune parameters were not evaluated.
TILs assessment
TILs evaluation was performed on haemoxylin and eosin-stained (HES) whole sections of either formalin-or acetic acid formalin alcohol (AFA)-fixed tissue. sTILs were defined as the percentage of total intra-tumoural stromal area occupied by mononuclear cells according to the method described by the International TILs Working Group 2014 [8, 12] . For ieTILs, defined as lymphocytes in direct contact with epithelium of tumour cell islets, a semi-quantitative assessment of infiltration yielded a score of 0-3 (0 ¼ no infiltration, 1 ¼ mild, 2 ¼ moderate, or 3 ¼ strong). TILs were assessed by two experienced pathologists (JA, CG), blinded to outcome data.
High sTILs were defined as 50% infiltration, high ieTILs as a score 2. Changes in sTILs and ieTILs were assessed in paired samples and defined as an absolute change of 10% or change in score 1, respectively.
PD-L1 expression
Immunohistochemical analysis for PD-L1 was performed on tissue microarrays (TMA) with clone E1L3N (Cell Signaling Technology, Danvers, MA) using a Ventana Discovery Ultra platform (Ventana, Tuscon AZ). Primary antibody was incubated at 1 mg/ml dilution for 1 h at room temperature. Detection was performed using a HQ amplification kit and 3,3
0 -diaminobenzidine as a chromogen. For each tumour sample, PD-L1 expression was scored by two pathologists (JA, CG), blinded to outcome data, and reported as the average percentage of cells with moderate to strong membranous staining in three TMA cores. PD-L1-positivity was defined as staining in 5% of cells. The PD-L1 assay could not be validated in tumour samples fixed with AFA, these samples were excluded from analysis. For a subset, PD-L1 expression was determined on both TMA cores and matched whole sections from the same tumours to assess correlation.
Evaluation of PD-L1 expression following cisplatin administration in OC cell lines
Studies of PD-L1 expression following treatment with cisplatin were performed in three OC cell lines (see Supplementary Methods S1, available at Annals of Oncology online).
Statistical analysis
Statistical analysis was performed using SAS v9.3 and Prism v6. Comparisons of categorical variables were performed using chi-squared tests and were exact where appropriate, while continuous variables were compared using Wilcoxon tests, with Pratt modification for paired samples. For categorical variables in paired samples, McNemar's test was used. Median follow-up was estimated using the Schemper method, survival curves were generated using the Kaplan-Meier method. Prognostic analyses were performed with a Cox model and for multivariate analysis adjusting on known independent prognostic factors. A P value of 0.05 was considered significant. Exploratory analysis was performed evaluating the association between high sTILs and PD-L1-positivity, and the impact of sTILs level pre-and post-NACT on PFI. This study was reported according to REMARK reporting criteria for prognostic tumour marker studies [13] .
Results
Baseline characteristics and clinical outcomes
A total of 150 patients were included in the study, baseline clinicopathological characteristics are summarized in Table 1 . Most patients (92%) had advanced disease deemed unresectable at presentation and received on an average four cycles of NACT with the goal of achieving complete cytoreduction. Supplementary Figure S1 , available at Annals of Oncology online, details the number of samples evaluable for each marker. Due to the small numbers of paired diagnostic and relapse samples, these were excluded from analysis.
With a median follow-up time of 52 months (95% CI 41-61 months), median PFS for the whole cohort was 20 months (95% CI 18-23), median overall survival (OS) was 51 months (95% CI 41-69).
Change in sTILs with NACT sTILs were detectable in all tumour samples (range 2-90% infiltration, supplementary Figure S2 and Table S1 , available at Annals of Oncology online). The median level of sTILs was 20% (IQR 10-40), 22% (25/113) of tumours showed high sTILs (50%). We detected no significant difference in levels of sTILs according to BRCA-mutation status or histology (supplementary Tables S2 and  S3 , available at Annals of Oncology online).
Among patients (N ¼ 83) with paired pre-and post-NACT samples, there was an overall significant increase in the level of sTILs following NACT (median sTILs 20% pre-to 30% post-NACT, P ¼ 0.0005, Figure 1A) . However, the impact of NACT was highly variable among individual patients, with half (42/83) showing an increase and a quarter (21/83) a decrease in sTILs post-NACT. sTILs remained stable in only 24% (20/83) of patients ( Figure 1B ). Among tumours classified as low sTILs at diagnosis, 21% (13/63) became high sTILs post-NACT. Conversely, among tumours showing high sTILs at diagnosis, 40% (8/20) converted to low sTILs post-NACT.
Given the association between PFI after first-line treatment and response to subsequent chemotherapy, the correlation between sTILs and PFI was evaluated. Among high-grade (serous, endometrioid or poorly differentiated) tumours, pre-NACT sTILs were not predictive of PFI. However, patients with a PFI of 6 months had significantly higher post-NACT sTILs compared to patients with a PFI of <6 months (median sTILs 28% PFI 6 months versus 18% PFI <6 months, P ¼ 0.026, Figure 1C ).
Change in ieTILs with NACT
At diagnosis, ieTILs were detectable in 81% (85/105) of tumours and 23% (24/105) showed a high ieTILs score. The evolution of ieTILs with chemotherapy was evaluated in patients with paired samples (N ¼ 76). ieTILs increased following NACT in 33% (25/ 76), remained stable in 43% (33/76) and decreased in 24% (18/ 76) of patients. Thirty-one percent (18/59) of low ieTILs tumours converted to high with NACT, while 59% (10/17) converted from high to low ieTILs.
Change in PD-L1 expression with NACT
Fewer tumours were evaluable for PD-L1 expression as older AFA fixed samples were excluded. In the evaluation of all available, unpaired tumours, using a cutoff of 5% to define PD-L1-positivity, the proportion with PD-L1 positive immune cells was 30% (15/ 50) at diagnosis, and significantly higher at 53% (27/51, P ¼ 0.026) post-NACT (supplementary Table S4 , available at Annals of Oncology online). PD-L1-positivity was much lower in tumour cells, although these also showed a higher proportion of PD-L1-positivity post-NACT (Figure 2A ). Correlation between PD-L1 expression on TMA cores and whole sections from individual patients was excellent (N ¼ 22, Spearman r ¼ 0.9, 95% CI 0.78-0.96, P < 0.0001). In line with our data in patient samples, PD-L1 expression was induced by cisplatin treatment in a dose-dependent fashion in two of three OC cell lines tested ( Figure 2E ).
In the subset of patients (N ¼ 27) with paired pre-and post-NACT tumour samples, the proportion with PD-L1-positive immune cells increased from 30% (8/27) pre-NACT to 63% (17/27) post-NACT (P ¼ 0.04), importantly among those PD-L1-negative at diagnosis, 63% (12/19) became positive after NACT (Figure 2B-D) .
Correlation between sTILs level and PD-L1 expression in post-chemotherapy tumours
In the analysis of 46 post-chemotherapy tumours samples with evaluable PD-L1 expression and sTILs data, there was a strongly positive relationship between the presence of high sTILs and PD-L1-positivity, with a tumour with high sTILs being significantly more likely to be PD-L1-positive (OR 9.0, 95% CI 1.7-47, P ¼ 0.005). 
Association of immune parameters with survival
In univariate and multivariate analysis, higher levels of pre-and post-NACT sTILs had a significant beneficial prognostic effect on PFS whether analysed as a continuous or categorical variable (Table 2; supplementary Table S5 and Figure S3 , available at Annals of Oncology online), although in multivariate continuous analysis of post-NACT tumours the P-value did not reach significance (HR 0.92, P ¼ 0.10). Patients with high versus low sTILs were balanced for standard prognostic factors for relapse (supplementary Table S6 , available at Annals of Oncology online). There was a trend towards improved OS for patients with high levels of post-NACT sTILs, this effect was not seen for high pre-NACT sTILs. In subgroup analysis of patients according to change in sTILs level with NACT, no significant difference in survival was detected between those with increased, decreased or stable sTILs. No association with survival was detected for ieTILs or PD-L1-positivity (Table 2) .
Discussion
We present the largest study to date evaluating the impact of platinum-based NACT on the lymphocytic infiltrate and PD-L1 expression in patients with EOC. We demonstrated for the first time that both sTILs and PD-L1 expression increased significantly following NACT. Our findings are supported by a small study in OC showing PD-L1 levels increase following NACT [15] , as well as our own and other pre-clinical data showing that chemotherapy upregulates PD-L1 in OC cell lines [6] . Importantly, when considering paired samples from individual patients, the immune modulatory effects of NACT were variable and likely reflect the heterogeneity of EOC. While over half of EOCs showed a recruitment of sTILs and/or ieTILs, a quarter showed a decrease in TILs suggesting that NACT may have either stimulatory or suppressive effects on the tumour microenvironment. Furthermore, one-fifth of patients with low sTILs at diagnosis converted to high sTILs post-NACT. Similarly, 63% of tumours PD-L1-negative at diagnosis became positive after initial standard treatment. An association between TILs and PD-L1 expression has previously been described in EOC [16] , in our study, patients with high sTILs post-chemotherapy were significantly more likely to be PD-L1-positive, suggesting activation of this immunosuppressive mechanism as a regulatory response to immune stimulation during chemotherapy. These results have obvious implications for future studies of maintenance immunotherapies, and underscore the critical importance of evaluating the post-NACT tumour, in order to integrate data on the diagnostic tumour immune profile and its evolution with chemotherapy. Immune checkpoint modulators, such as PD-1/PD-L1 antibodies do not recruit lymphocytes, but rather release the break on cytotoxic T-cell activity, and PD-1/PD-L1 blockade has been shown to be more effective in tumours with pre-existing lymphocytic infiltration [17, 18] . In addition, therapeutic responses to PD-L1 inhibition have been correlated with PD-L1 expression [19] . Although our results require validation, they suggest that in EOC, PD-1/PD-L1 blockade immediately post-NACT could be particularly beneficial in patients with an abundant PD-L1-positive immune infiltrate that has been harnessed during chemotherapy. We evaluated the prognostic relevance of the post-NACT immune profile. The level of pre-NACT sTILs was not predictive of PFI after initial treatment, however high post-NACT sTILs P r e P o s t P r e P o s t P r e P o s t P r e P o s t predicted subsequent platinum-responsiveness (PFI 6 months). Furthermore, both high pre-and post-NACT sTILs were independent prognostic factors for PFS. Taken together, these results suggest that adaptive immunogenic mechanisms during NACT may contribute to PFI, survival outcome, and help identify patients for immunotherapies. In line with our data, other smaller studies in EOC have demonstrated an increase in activated T-cells following chemotherapy [6, 15, 20] , with one of these studies showing that a high ratio of granzyme-Bþ to T-regulatory cells post-chemotherapy predicted improved survival [20] . Despite the paucity of evidence for their value in EOC, we evaluated TILs in the stromal compartment, and our results lend importance to this parameter as an immune biomarker in EOC. Rationale for this was based on the strength of evidence validating the prognostic benefit of sTILs in triple-negative breast cancer [7, 21, 22] a disease with genomic homology to high-grade serous OC, and in accordance with these studies, we followed the recommendations of the International TILs Working Group for evaluation of sTILs on whole HES-sections [8] . In EOC, no clinically relevant threshold has been defined for lymphocyte-predominant tumours. We were guided by studies in breast cancer where the threshold has been defined as 50%, an easily quantifiable cut-off that has repeatedly predicted improved survival [7, 8, 12, 21] . This phenotype, implying a robust anti-tumour immune response, was seen in at least one-fifth of EOC patients.
Our study detected no association between ieTILs score and survival, however due to lack of immune cell markers and heterogeneity, assessment of ieTILs on an HES-section is considered less reliable and reproducible than assessment of sTILs [8] . This limitation of our study likely explains our results which are in contrast to previously published studies in EOC.
The evaluation of PD-L1 expression in this study was performed by a method similar to that used by Herbst et al. [19] who demonstrated that PD-L1 expression on immune, but not tumour cells, strongly predicted response to PD-L1 blockade in several tumour types. In EOC, we found that PD-L1 expression was common and predominantly seen in immune cells, with a low level of positivity in tumour cells (0% of pre-chemotherapy P r e P o s t P r e P o s t P r e P o s t tumours and 12% of post-chemotherapy tumours). This study does not account for contribution of intra-tumoural heterogeneity, however work is ongoing to assess TILs in a cohort with multiple biopsies from anatomically distinct sites. Treatment of EOC remains a significant challenge with an unmet need for new strategies to reduce the high rates of relapse and mortality among patients with advanced disease. Trials of immunotherapy in EOC have been conducted in unselected, heavily pre-treated patients with potential immune exhaustion [11] . A more appropriate strategy may be immunotherapy as maintenance after primary treatment, in order to harness the host immune system and target the minimal residual disease that drives relapse.
In conclusion, our study showed that NACT can have a significant impact on the tumour microenvironment, with more than half of EOCs showing increased lymphocytic infiltration and upregulation of PD-L1 expression post-chemotherapy. Whether this is attributable to cytotoxicity-induced antigen release in these typically chemosensitive tumours is unknown. Work is ongoing to characterize the immune subpopulations recruited to the stromal and intra-epithelial compartments, and to evaluate the impact of NACT on co-regulatory molecules. On multivariate analysis, high sTILs remained prognostic post-NACT. Given evidence that the benefit of immunotherapy may depend on an individual's antitumour immune response, our data suggest that evaluation of this response after initial NACT should be used to guide selection of maintenance therapy. In the future, one could envisage a truly personalized approach, whereby after initial treatment patients with EOC are stratified to maintenance according to both tumour and immune factors. Patients with a lymphocyte-predominant, PD-L1-positive tumour microenvironment post-NACT could be offered PD-1/PD-L1 blockade as maintenance. Those with lymphocyte-poor, PD-L1-positive tumours post-NACT could be treated with both PD-1/PD-L1 blockade in combination with an immunotherapy designed to increase T-cell infiltration. Finally, patients whose tumours are relatively lymphocyte-poor and PD-L1-negative may be more appropriately directed to clinical trials of molecular therapies. P values for univariate and multivariate analysis were derived from tests on Cox models, in multivariate analysis, adjustment was made for completeness of resection.
